Automatically computed rating scales from MRI for patients with cognitive disorders
- PMID: 30796570
- DOI: 10.1007/s00330-019-06067-1
Automatically computed rating scales from MRI for patients with cognitive disorders
Abstract
Objectives: The aims of this study were to examine whether visual MRI rating scales used in diagnostics of cognitive disorders can be estimated computationally and to compare the visual rating scales with their computed counterparts in differential diagnostics.
Methods: A set of volumetry and voxel-based morphometry imaging biomarkers was extracted from T1-weighted and FLAIR images. A regression model was developed for estimating visual rating scale values from a combination of imaging biomarkers. We studied three visual rating scales: medial temporal lobe atrophy (MTA), global cortical atrophy (GCA), and white matter hyperintensities (WMHs) measured by the Fazekas scale. Images and visual ratings from the Amsterdam Dementia Cohort (ADC) (N = 513) were used to develop the models and cross-validate them. The PredictND (N = 672) and ADNI (N = 752) cohorts were used for independent validation to test generalizability.
Results: The correlation coefficients between visual and computed rating scale values were 0.83/0.78 (MTA-left), 0.83/0.79 (MTA-right), 0.64/0.64 (GCA), and 0.76/0.75 (Fazekas) in ADC/PredictND cohorts. When performance in differential diagnostics was studied for the main types of dementia, the highest balanced accuracy, 0.75-0.86, was observed for separating different dementias from cognitively normal subjects using computed GCA. The lowest accuracy of about 0.5 for all the visual and computed scales was observed for the differentiation between Alzheimer's disease and frontotemporal lobar degeneration. Computed scales produced higher balanced accuracies than visual scales for MTA and GCA (statistically significant).
Conclusions: MTA, GCA, and WMHs can be reliably estimated automatically helping to provide consistent imaging biomarkers for diagnosing cognitive disorders, even among less experienced readers.
Key points: • Visual rating scales used in diagnostics of cognitive disorders can be estimated computationally from MRI images with intraclass correlations ranging from 0.64 (GCA) to 0.84 (MTA). • Computed scales provided high diagnostic accuracy with single-subject data (area under the receiver operating curve range, 0.84-0.94).
Keywords: Atrophy; Cognition disorders; Magnetic resonance imaging.
Similar articles
-
A new age-related cutoff of medial temporal atrophy scale on MRI improving the diagnostic accuracy of neurodegeneration due to Alzheimer's disease in a Chinese population.BMC Geriatr. 2019 Feb 28;19(1):59. doi: 10.1186/s12877-019-1072-8. BMC Geriatr. 2019. PMID: 30819102 Free PMC article.
-
Combining Visual Rating Scales for Medial Temporal Lobe Atrophy and Posterior Atrophy to Identify Amnestic Mild Cognitive Impairment from Cognitively Normal Older Adults: Evidence Based on Two Cohorts.J Alzheimers Dis. 2020;77(1):323-337. doi: 10.3233/JAD-200016. J Alzheimers Dis. 2020. PMID: 32716355 Clinical Trial.
-
Practical cut-offs for visual rating scales of medial temporal, frontal and posterior atrophy in Alzheimer's disease and mild cognitive impairment.J Intern Med. 2015 Sep;278(3):277-90. doi: 10.1111/joim.12358. Epub 2015 Apr 13. J Intern Med. 2015. PMID: 25752192
-
Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.Neurobiol Aging. 2017 Apr;52:167-182.e1. doi: 10.1016/j.neurobiolaging.2016.05.024. Neurobiol Aging. 2017. PMID: 28317647 Review.
-
Imaging biomarkers of dementia: recommended visual rating scales with teaching cases.Insights Imaging. 2017 Feb;8(1):79-90. doi: 10.1007/s13244-016-0521-6. Epub 2016 Dec 21. Insights Imaging. 2017. PMID: 28004274 Free PMC article. Review.
Cited by
-
Towards validation in clinical routine: a comparative analysis of visual MTA ratings versus the automated ratio between inferior lateral ventricle and hippocampal volumes in Alzheimer's disease diagnosis.Neuroradiology. 2024 Apr;66(4):487-506. doi: 10.1007/s00234-024-03280-8. Epub 2024 Jan 19. Neuroradiology. 2024. PMID: 38240767 Free PMC article.
-
The Healthy Brain 9 (HB9): A new instrument to characterize subjective cognitive decline, and detect anosognosia in mild cognitive impairment.PLoS One. 2025 Jun 24;20(6):e0322351. doi: 10.1371/journal.pone.0322351. eCollection 2025. PLoS One. 2025. PMID: 40554536 Free PMC article.
-
Voxel-based morphometry in single subjects without a scanner-specific normal database using a convolutional neural network.Eur Radiol. 2024 Jun;34(6):3578-3587. doi: 10.1007/s00330-023-10356-1. Epub 2023 Nov 9. Eur Radiol. 2024. PMID: 37943313 Free PMC article.
-
The Healthy Brain 9 (HB9): A New Instrument to Characterize Subjective Cognitive Decline, and Detect Anosognosia in Mild Cognitive Impairment.medRxiv [Preprint]. 2025 Mar 23:2025.03.23.25324480. doi: 10.1101/2025.03.23.25324480. medRxiv. 2025. Update in: PLoS One. 2025 Jun 24;20(6):e0322351. doi: 10.1371/journal.pone.0322351. PMID: 40166560 Free PMC article. Updated. Preprint.
-
Regional MRI volumetry using NeuroQuant versus visual rating scales in patients with cognitive impairment and dementia.Brain Behav. 2024 Feb;14(2):e3397. doi: 10.1002/brb3.3397. Brain Behav. 2024. PMID: 38600026 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical